ArticleBMC urology2025
The diagnostic value of urinary exosomes in prostate cancer: a prospective multicenter study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques.Diseases (Basel, Switzerland) · 2026Review
- Extracellular vesicles in prostate cancer: current understanding and future perspectives.Journal of the National Cancer Center · 2026Review
- Tumor exosomes impact functional hallmarks of cancer.Cancer metastasis reviews · 2026Review
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
- Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications.Extracellular vesicles and circulating nucleic acids · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe diagnosis of prostate cancer (PCa) relies on prostate-specific antigen (PSA) in blood, but the specificity of PSA remains inadequate. This study aims to develop and validate a highly efficient and accurate diagnostic model based on urinary exosomes combined with machine learning (ML) techniques, to identify PCa patients at an early stage and provide support for clinical decision-making.
methodsThis study included 287 patients from Shanghai Changhai Hospital, Shanghai Shibei Hospital, and Taizhou People's Hospital, consisting of 89 PCa patients and 198 benign prostatic hyperplasia (BPH) patients. Urinary exosomes were collected from these patients. LASSO regression was used to screen key variables, and nine ML algorithms (including XGBoost, random forest, and logistic regression) were employed to construct the diagnostic model. Model performance was evaluated using AUC, learning curves, calibration curves, and decision curve analysis (DCA), and the contributions of key predictors were visualized using the SHAP method.
resultsAmong the 11 clinical features included, 3 key features were selected: u-PSA, u-PSMA, and u-AMACR. Among the nine algorithms, the GBDT model performed best, achieving an AUC of 1.000 in the training cohort and 0.987 in the validation cohort. SHAP analysis showed that u-PSA, u-PSMA, and u-AMACR were the most important predictors for PCa. The learning curves indicated that the model fit well and remained stable, while DCA demonstrated significant clinical net benefit, and the calibration curves indicated good diagnostic performance.
conclusionThe urinary exosome-based PCa diagnostic model demonstrates high diagnostic efficacy and can assist physicians in better identifying PCa, reducing unnecessary biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.